Abstract Number: 0592 • ACR Convergence 2024
Sustained Improvements with Bimekizumab in Patient-Reported Symptoms of Axial Spondyloarthritis: 2-Year Results from Two Phase 3 Studies
Background/Purpose: In the phase 3 studies, BE MOBILE 1 and 2, bimekizumab (BKZ), a monoclonal IgG1 antibody that selectively inhibits interleukin (IL)-17F in addition to…Abstract Number: 0795 • ACR Convergence 2024
Prevalence of Post-exertional Malaise (PEM) in Adults with Rheumatic Diseases and Relationship with COVID19 Infection
Background/Purpose: Chronic fatigue is the dominant symptom in patients with Long COVID and Myalgic encephalomyelitis/Chronic fatigue syndrome (ME/CFS) as well as an important and prevalent…Abstract Number: 0987 • ACR Convergence 2024
Correlates of Depression in Individuals with Chronic Fatigue Syndrome
Background/Purpose: Chronic fatigue syndrome (CFS) is a multifaceted illness with a wide range of symptoms. It shares similar symptomatology with depression. In situations where patients have both…Abstract Number: 1278 • ACR Convergence 2024
The Effects of Fatigue on Self-Reported Mental and Physical Health in Childhood-Onset Systemic Lupus Erythematosus: A Cross-Sectional Study
Background/Purpose: Fatigue is a prevalent and distressing symptom in childhood-onset systemic lupus erythematosus (cSLE), affecting up to 74% of patients with potential for adverse effects…Abstract Number: 1280 • ACR Convergence 2024
Abnormal Cortical Gyrification Patterns in Adolescents with Childhood-onset SLE: Early Associations with Perceived Fatigue
Background/Purpose: Fatigue and brain fog are early complaints in adolescents with childhood-onset SLE (cSLE), who experience disease onset during a critical period of brain development.…Abstract Number: 1320 • ACR Convergence 2024
Acceptability and Satisfaction of an Online Resilience-Building Intervention with Peer Health Coaches for Managing Fatigue and Well-Being in Systemic Sclerosis
Background/Purpose: Non-pharmacological fatigue management interventions in systemic sclerosis (SSc) are limited, despite people with SSc reporting that fatigue is inadequately addressed with clinical care. We…Abstract Number: 1520 • ACR Convergence 2024
The Influence of Trauma on Features of Type 2 SLE
Background/Purpose: Type 2 SLE symptoms of fatigue, widespread pain, sleep and cognitive dysfunction occur commonly in SLE although their etiology is unknown. Since trauma has…Abstract Number: 1555 • ACR Convergence 2024
Sustained Functional Assessment of Chronic Illness Therapy–Fatigue Response in Patients with SLE Receiving Anifrolumab Alongside Standard Therapy
Background/Purpose: Fatigue is highly prevalent and severely affects health-related quality of life (HRQoL) in patients with SLE.1,2 We previously demonstrated that, compared with placebo, a…Abstract Number: 1937 • ACR Convergence 2024
Wellness and Burnout Among Pediatric Rheumatologists in North America- A 2024 CARRA Study
Background/Purpose: A high proportion of pediatricians experience burnout symptom impacting patient care and academic productivity. Burnout is a state of physical, emotional or mental exhaustion…Abstract Number: 2002 • ACR Convergence 2024
Pain and Physical Function, but Not Fatigue, Track with Disease Activity in Immune Checkpoint Inhibitor-Induced Inflammatory Arthritis
Background/Purpose: Immune checkpoint inhibitor-induced inflammatory arthritis (ICI-IA) is an impactful and often persistent side effect of cancer immunotherapy that can lead to permanent joint damage…Abstract Number: 2029 • ACR Convergence 2024
Iron Deficiency in Familial Mediterranean Fever: A Study on 211 Adult Patients from the JIR Cohort
Background/Purpose: Familial Mediterranean fever (FMF) is the most common monogenic autoinflammatory disease worldwide. Fatigue is known to trigger FMF attacks. So far, no association has…Abstract Number: 2225 • ACR Convergence 2024
Role of Fatigue in Difficult to Treat Rheumatoid Arthritis
Background/Purpose: A subset of patients with rheumatoid arthritis (RA) who remains symptomatic after failing to multiple therapies are deemed to have "difficult-to-treat" (D2T RA). Fatigue…Abstract Number: 0357 • ACR Convergence 2024
Evaluating Meaningful Within-Person Change Thresholds in PROMIS-Fatigue Scores from Three Phase 3 Clinical Trials of Sarilumab for Rheumatoid Arthritis Using Empirical Cumulative Distribution Function (eCDF) Curves
Background/Purpose: To evaluate changes over time in fatigue measured by Patient Reported Outcome Measures Information System (PROMIS)-Fatigue scores in rheumatoid arthritis (RA) patients treated with…Abstract Number: 2368 • ACR Convergence 2024
Bimekizumab-Treated Patients with Active Psoriatic Arthritis Showed Sustained Improvements in Pain and Fatigue: Up to 2-Year Results from Two Phase 3 Studies
Background/Purpose: PsA significantly impacts patients' quality of life due to functional limitations, pain, and fatigue.1 Sustained relief from pain and fatigue are therefore important aims…Abstract Number: 0358 • ACR Convergence 2024
Residual’ Fatigue and Its Severity in Patients with Rheumatoid Arthritis in Clinical Remission: Prevalence and Associated Factors
Background/Purpose: Fatigue is a frequent and annoying symptom in rheumatoid arthritis (RA) patients that is often not assessed at routine follow-up visits. Residual’ fatigue has…
- 1
- 2
- 3
- …
- 14
- Next Page »